Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.
Travere Therapeutics Inc. submitted a New Drug Application to the U.S. Food and Drug Administration under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
One week after expanding the company’s neurodegenerative diseases partnership with Bristol Myers Squibb, Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
Vifor Pharma and Travere Therapeutics inked a collaboration and licensing partnership to commercialize sparsentan in Europe, Australia and New Zealand. The drug is being developed to treat FSGS and IgAN, which are rare progressive kidney diseases that are leading causes of end-stage kidney disease.
After the historic approval of the company’s first-ever drug in January 2021, Aurinia Pharmaceuticals announced the acquisition of two pipeline assets that align with the Canadian biotech’s focus on autoimmune and kidney-related disease.
Novartis announced Phase II primary endpoint data showing the investigational, first-in-class, oral, targeted factor B inhibitor iptacopan reduced protein in the urine – an increasingly recognized surrogate marker correlating with progression to kidney failure – and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN).
Sanofi is halting a pivotal Phase II/III kidney disease trial for venglustat, a novel molecule designed to slow disease progression by inhibiting abnormal accumulation of glycosphingolipids.
The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace FibroGen presented data from two pooled analyses from its roxadustat global […]